Online inquiry

IVTScrip™ mRNA-Anti-ITGAV&ITGB3, CNTO 095(Cap 0, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ5992MR)

This product GTTS-WQ5992MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets ITGAV&ITGB3 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001144999.3; NM_000212.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3685; 3690
UniProt ID P06756; P05106
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ITGAV&ITGB3, CNTO 095(Cap 0, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ5992MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10631MR IVTScrip™ mRNA-Anti-MAPT, LY-3303560(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA LY-3303560
GTTS-WQ12078MR IVTScrip™ mRNA-Anti-CD19, MOR-00208(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA MOR-00208
GTTS-WQ7479MR IVTScrip™ mRNA-Anti-TGFB, GC-1008(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA GC-1008
GTTS-WQ7181MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-28Z CAR(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA FMC63 scFv-28Z CAR
GTTS-WQ215MR IVTScrip™ mRNA-Anti-IL13, 13C5.5(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA 13C5.5
GTTS-WQ8050MR IVTScrip™ mRNA-Anti-F, H1H3592P3(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA H1H3592P3
GTTS-WQ3351MR IVTScrip™ mRNA-Anti-MS4A1, AT-004(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA AT-004
GTTS-WQ15066MR IVTScrip™ mRNA-Anti-KDR, SSS-23(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA SSS-23
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW